PriceTargets.com logo

NASDAQ:SRZN - Surrozen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.50
  • Forecasted Upside: 466.86 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.44 As of 07/5/2022 04:56 PM ET
▲ +0.29 (9.21%)

This chart shows the closing price for SRZN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Surrozen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRZN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRZN

Analyst Price Target is $19.50
▲ +466.86% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Surrozen in the last 3 months. The average price target is $19.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 466.86% upside from the last price of $3.44.

This chart shows the closing price for SRZN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Surrozen.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/27/2022Bank of AmericaDowngradeBuy ➝ NeutralHigh
10/11/2021Bank of AmericaInitiated CoverageBuyLow
9/15/2021GuggenheimInitiated CoverageBuy$20.00High
9/7/2021Stifel NicolausInitiated CoverageBuy$19.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/7/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/6/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Surrozen logo
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.44
Low: $3.10
High: $3.44

50 Day Range

MA: $2.65
Low: $2.14
High: $3.43

52 Week Range

Now: $3.44
Low: $1.98
High: $14.00

Volume

343 shs

Average Volume

10,178 shs

Market Capitalization

$120.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Surrozen?

The following Wall Street research analysts have issued research reports on Surrozen in the last year: Bank of America Co., Guggenheim, and Stifel Nicolaus.
View the latest analyst ratings for SRZN.

What is the current price target for Surrozen?

0 Wall Street analysts have set twelve-month price targets for Surrozen in the last year. Their average twelve-month price target is $19.50, suggesting a possible upside of 466.9%.
View the latest price targets for SRZN.

What is the current consensus analyst rating for Surrozen?

Surrozen currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRZN will outperform the market and that investors should add to their positions of Surrozen.
View the latest ratings for SRZN.

How do I contact Surrozen's investor relations team?

Surrozen's physical mailing address is 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540. The company's listed phone number is 650-489-9000 and its investor relations email address is [email protected] The official website for Surrozen is www.consonancehfw.com. Learn More about contacing Surrozen investor relations.